Treatment of acne vulgaris: a literature review / Lečenje običnih akni (acne vulgaris) – pregled literature

1. Lello J, Pearl A, Arroll B. Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J 1995;08:287-9.Search in Google Scholar

2. Gollnick H,Cunliffe W, Berson D, et al. Management of acne: a report from Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003;49(1 Suppl):S1-37.10.1067/S0190-9622(03)02455-1Search in Google Scholar

3. Kubba R, Ajaj AK, Thappa DM, et al. Acne in India: guidelines for management-IAA consensus document. Genetics in acne. Indian J Dermatol Venereol Leprol 2009;75(Suppl 1):S4.Search in Google Scholar

4. Cunliffe WJ, Gollnick HPM. Acne: diagnosis and management. London: Martin Dunitz; 2001.p.1-46.Search in Google Scholar

5. Yazici K, Baz K, Yazici AE, Kokturk A, Tot S, Demirseren D, et al. Disease-specific quality of life associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venerol 2004;18:435-9.10.1111/j.1468-3083.2004.00946.xSearch in Google Scholar

6. Dreno B. Assessing quality of life in patients with acne vulgaris. Am J Clin Dermatol 2006;7(2):99-106.10.2165/00128071-200607020-00003Search in Google Scholar

7. Ahmed S, Ahmed I. Frequency and magnitude of anxiety and depression among acne patients: a study of 100 cases. J Liaquat Uni Med Health Sci 2007;6(1):25-9.10.22442/jlumhs.07610110Search in Google Scholar

8. Burke BM, Cunliffe WJ. The assessment of acne vulgaris: leeds technique. Br J Dermatol 1984;111:83-92.10.1111/j.1365-2133.1984.tb04020.xSearch in Google Scholar

9. Baldwin H. Tricks for improving compliance with acne therapy. Dermatol Ther 2006;19:224-36.10.1111/j.1529-8019.2006.00078.xSearch in Google Scholar

10. Thielitz A, Gollnick H. Topical retinoids in acne vulgaris. Am J Clin Dermatol 2008;9(6):369-81.10.2165/0128071-200809060-00003Search in Google Scholar

11. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol 1998;39: S38-44.10.1016/S0190-9622(98)70443-8Search in Google Scholar

12. Lucky AW, Cullen SI, Jarratt MT, et al. Comparative efficacy and safety of two 0.0025% tretinoin gels: results from multicenter double-blind, parallel study. J Am Acad Dermatol 1998;38(4):S17-23.Search in Google Scholar

13. Irby CE, Yentzer BA, Feldman SR. A review of adapalene in the treatment of acne vulgaris. J Adolesc Health 2008;43:421-4.10.1016/j.jadohealth.2008.06.005Search in Google Scholar

14. Laboratories, Differin (adapalene) 0.3% gel product insert information, United States (online). Available from: URL:http:// www.differin.com/AboutDifferin/ProductInsert_Gel 0,3. aspx [Accessed 2010 Jan 28].Search in Google Scholar

15. Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet 1993;341:1181-2.10.1016/0140-6736(93)91004-6Search in Google Scholar

16. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997;37(Suppl 2 Pt 1):S12-7.10.1016/S0190-9622(97)80395-7Search in Google Scholar

17. Bershad S, Kranjac, Singer G, Parente J, Tan MH, Sherer D, Persuad AN, et al. Successful treatment of acne vulgaris using a new method. Arch Dermatol 2002;38:481-9.10.1001/archderm.138.4.481Search in Google Scholar

18. Krautheim A, Gollnick H. Acne: topical treatment. Clin Dermatol 2004;22:398-407.10.1016/j.clindermatol.2004.03.009Search in Google Scholar

19. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005;153:395-403.10.1111/j.1365-2133.2005.06614.xSearch in Google Scholar

20. Poljački M, Subotić M, Đuran V, Matic M, Ivkov M. Terapija vulgarnih akni lokalnom elektroforetskom primenom klindamicina. U: II Kongres pedijatara Jugoslavije: zbornik sažetaka; 1998 sept. 20-26; Novi Sad, Jugoslavija. Novi Sad: Udruženje pedijatara Jugoslavije; 1998. str. 303-5.Search in Google Scholar

21. Coates P, Vyakrnam S, Eady EA, Jones CE, Cove JH, Cunliffe WJ. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients:10-year surveillance data and snapshot distribution study. Br J Dermatol 2002;146:840-8.10.1046/j.1365-2133.2002.04690.xSearch in Google Scholar

22. Ross JI, Snelling AM, Carnegie E, Coates P, Cunliffe WJ, Bettoli V, et al. Antibiotic-resistant acne: lessons from Europe. Br J Dermatol 2003;148:467-78.10.1046/j.1365-2133.2003.05067.xSearch in Google Scholar

23. Cooper AJ. Systemic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998;169:259-61.10.5694/j.1326-5377.1998.tb140250.xSearch in Google Scholar

24. Lookingbill DP, Chalker DK, Lindholm JS. Treatment of acne with combination of clindamycin/bezoylperoxyd gel compared with clindamycin gel, benzoylpreoxyde gel and combined results of two double blind investigations. J Am Acad Dermatol 1997;37:590-5.10.1016/S0190-9622(97)70177-4Search in Google Scholar

25. Katsambas A, Graupe K, Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm Venereol Suppl (Stockh) 1989;143:35-9.Search in Google Scholar

26. Zhu YI, Stiller MJ. Dapsone and sulphones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34.10.1067/mjd.2001.11473311511841Search in Google Scholar

27. Draelos ZD, Carter E, Maloney MJ, Elewski B, Poulin Y, Lynde C, et al. Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris. J Am Acad Dermatol 2007;439:e1-10.10.1016/j.jaad.2006.10.00517208334Search in Google Scholar

28. Piette W, Taylor S, Pariser D, Jarratt M, Pranav S, Wilson D. hematologic safety of dapsone gel 5%, for topical treatment of acne vulgaris. Arch Dermatol 2008;144:1564-70.10.1001/archdermatol.2008.51819075138Search in Google Scholar

29. Gruber D, Sator M, Joura E, Kokoschka EM, Heinze G, Huber J. Topical cyproterone acetate treatment in women with acne. Arch Dermatol 1998;134:459-63.10.1001/archderm.134.4.4599554298Search in Google Scholar

30. Papageorgiou P, Kartsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. Br J Dermatol 2000;142:973-8.10.1046/j.1365-2133.2000.03481.x10809858Search in Google Scholar

31. Charakida A, Seaton E, Charakida M, Mouser P, Avgerinos A, Chu A. Phototherapy in the treatment of acne vulgaris. Am J Clin Dermatol 2004;5(4):211-6.10.2165/00128071-200405040-0000115301568Search in Google Scholar

32. Morton CA, et al. Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. Br J Dermatol 2002;146:552-67.10.1046/j.1365-2133.2002.04719.x11966684Search in Google Scholar

33. Friedman P, Ming J, Kimyai-Asadi A, Goldberg L. Treatment of inflammatory facial acne vulgaris with the 1450-nm diode laser: a pilot study. Dermatol Surg 2004;30:147-51.10.1097/00042728-200402000-00006Search in Google Scholar

34. Goodman GJ. Management of post-acne scarring. What are the options for treatment? Am J Clin Dermatol 2000;1:3-17.10.2165/00128071-200001010-0000111702303Search in Google Scholar

35. Dreno B. Acne: physical treatment. Clin Dermatol 2004;22:429-33.10.1016/j.clindermatol.2004.03.01715556730Search in Google Scholar

36. Tan HH. Antibacterial therapy for acne. Am J Clin Dermatol 2003;4(5):307-14.10.2165/00128071-200304050-0000212688836Search in Google Scholar

37. Garner SE, Eady EA, Popescu C, et al. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2000;(2):CD002086.10.1007/BF03082691Search in Google Scholar

38. Sturkenboom MC, Meier CR, Jick H, et al. Minocyclin and lupus-like syndrome in acne patients. Arch Intern Med 1999;28:392-7.Search in Google Scholar

39. Bardazzi F, et al. Azitromycin: a new therapeutical strategy for acne in adolescents. Dermatol Online J 2008;13(4):4.Search in Google Scholar

40. Cooper AJ. Treatment of acne with isotretinoin: recommendations based on Australian experience. Aust J Dermatol 2003;44:97-105.10.1046/j.1440-0960.2003.00653.xSearch in Google Scholar

41. Poljački M, Gajinov Z, Subotić M, Đuran V, Matić M. Izotretinoin u dermatoloskoj praksi. Med Pregl 1996;49(5-6):199-202.Search in Google Scholar

42. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. Int J Neurobiol 2006;66:606-30.10.1002/neu.20242Search in Google Scholar

43. Reactive Holding Statement for postmarketing reports of severe skin reactions with use of isotretinoin. Basel: Roche; 2009.Search in Google Scholar

44. Chee Hong Ng, Schweitzer I. The association between depression and isotretinoin use in acne. Ausst N Z J Psychiatry 2003;37(1):78-84.10.1046/j.1440-1614.2003.01111.xSearch in Google Scholar

45. Rubinow DR, Peck GL, Squillace KM, et al. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987;17:25-32.10.1016/S0190-9622(87)70166-2Search in Google Scholar

46. White GM, Chen W, Yao J, et al. Recurrence rate after first course of isotretinoin. Arch Dermatol 1998;134:376-8.10.1001/archderm.134.3.3769521042Search in Google Scholar

47. Huber J, Walch K. Treating acne with oral contraceptives: use of lower doses. Contraception 2006;73:23-9.10.1016/j.contraception.2005.07.01016371290Search in Google Scholar

48. Muhlemann MF, Carter GD, Cream JJ, Wise P. Oral spironolactone: an effective treatment for acne vulgaris in women. Br J Dermatol 1988;115:227-32.10.1111/j.1365-2133.1986.tb05722.x2943311Search in Google Scholar

49. Thilboutot D. Acne: hormonal concepts and therapy. Clin Dermatol 2004;22:419-28.10.1016/j.clindermatol.2004.03.01015556729Search in Google Scholar

50. Zouboulis C, Nestoris S, Adler YD, et al. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipooxygenase inhibitor. Arch Dermatol 2003;139:668-70. 7.10.1001/archderm.139.5.66812756111Search in Google Scholar

51. Zouboulis CC, Seltmann H, Alestas T. Zileuton prevents the activation of the leukotriene pathway and reduces sebaceous lipogenesis. Exp Dermatol 2010;19:148-50.10.1111/j.1600-0625.2009.00929.x19645854Search in Google Scholar

52. Zouboulis CCh, Saborowski A, Boschnakow A. Zileuton, an Oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005;210:36-8.10.1159/00008148115604543Search in Google Scholar

53. Farrar M, Howson K, Bojar R, et al. Genome sequence and analysis of a Propionibacterium acnes bacteriophage. J Bacteriol 2007;189(11):4161-7.10.1128/JB.00106-07191340617400737Search in Google Scholar

54. Nakatsuji T, Liu YT, Huang CP, Gallo R, Huang CM. antibodies elicited by inactivated Propionibacterium acnesbased vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: prevalence to therapy for acne vulgaris. J Invest Dermatol 2008;128:2451-7.10.1038/jid.2008.117307041918463682Search in Google Scholar

55. Kim J. Acne vaccines: therapeutic option for the treatment of acne vulgaris? J Invest Dermatol 2008;128:2451-7. Search in Google Scholar